Shelby Hogan
Nurse Practitioner · Lewes, DENPI 1104589571
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,032 and has fallen 66.1% since, to $689 in 2025. Among nurse practitioner clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $27.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$767
- Amgen$704
- Pfizer$495
- AstraZeneca$449
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$384
- Boehringer Ingelheim$377
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,14898%
- Education$1172%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $767 |
| Amgen | 18 | $704 |
| Pfizer | 21 | $495 |
| AstraZeneca | 20 | $449 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $384 |
| Boehringer Ingelheim | 17 | $377 |
| Novartis | 13 | $294 |
| Boston Scientific | 7 | $280 |
| Medtronic | 9 | $275 |
| Johnson & Johnson(2 entities) | 11 | $227 |
| E.r. Squibb & Sons, L.L.C. | 6 | $214 |
| Esperion Therapeutics, Inc. | 7 | $129 |
| Lilly USA, LLC | 5 | $105 |
| Lexicon Pharmaceuticals, Inc. | 3 | $89 |
| Abiomed | 1 | $76 |
| AbbVie | 3 | $52 |
| Heartflow, Inc. | 2 | $48 |
| Sun Pharmaceutical Industries Inc. | 2 | $48 |
| Azurity Pharmaceuticals, Inc. | 1 | $35 |
| Lundbeck LLC | 2 | $33 |
| Baxter Healthcare | 2 | $32 |
| Medicomp Inc | 1 | $28 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Terumo Medical Corporation | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Merck | 1 | $18 |
| LEO Pharma Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,265 in reported general payments places this provider in the 95th percentile of 487 nurse practitioner providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 233 | $328,933 |
| Repatha SureclickEvolocumab | 119 | $169,617 |
| EntrestoSacubitril/Valsartan | 86 | $149,368 |
| XareltoRivaroxaban | 91 | $108,833 |
| JardianceEmpagliflozin | 48 | $75,090 |
| FarxigaDapagliflozin Propanediol | 35 | $50,974 |
| Praluent PenAlirocumab | 32 | $39,010 |
| OzempicSemaglutide | 16 | $28,868 |
| Repatha PushtronexEvolocumab | 13 | $21,934 |
| BrilintaTicagrelor | 14 | $18,187 |
| Ranolazine ErRanolazine | 62 | $8,956 |
| Nebivolol Hcl | 136 | $8,843 |
| Rosuvastatin Calcium | 358 | $8,370 |
| Prasugrel Hcl | 40 | $7,122 |
| Metoprolol Succinate | 366 | $6,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $495 | $328,933233 claims |
| NovartisEntresto | $294 | $149,36886 claims |
| Johnson & JohnsonXarelto | $227 | $108,83391 claims |
| Boehringer IngelheimJardiance | $377 | $75,09048 claims |
| AstraZenecaFarxiga, Brilinta | $449 | $69,16149 claims |
| Novo NordiskOzempic | $767 | $28,86816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 487 nurse practitioner providers in Delaware.
Other nurse practitioner in Lewes
- Jennifer ShadeLewes$4K
- Susan ParksLewes$3K
- Amanda CaputoLewes$3K
- Jennifer WilleyLewes$3K
- Deborah TabulovLewes$2K
- Meghan McCarterSeaford$170K
- Chandni PatelMiddletown$113K
- Craig LaingMilford$51K
- Colleen DitroWilmington$16K
- Sedelle Henderson-BamideleNewark$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.